NEWS
Potential Oral Therapy for HAE Seen To Be Effective as Firazyr in Monkey Model
| Angiodema News

A small molecule inhibitor being developed for hereditary angioedema (HAE) treatment, called PHA121, was as effective as Firazyr (icatibant acetate) — an approved therapy with a similar mechanism of action — at reversing bradykinin-induced changes in blood pressure in monkeys, results of a preclinical study show. Pharvaris‘s oral investigative treatment also exerted an effect on blood pressure faster than Firazyr in […]

Wall Street hails Chimerix viral load; COVID-19, smallpox bids forge onward
| BioWorld

A pair of good-news items from Chimerix Inc. pushed the Durham, N.C.-based company’s stock (NASDAQ:CMRX) to $2.15, closing up 64 cents, or 42%, higher as backers reacted to near-term NDA plans for smallpox countermeasure brincidofovir (BCV) and the start of a phase II/III trial with dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI). CEO Mike Sherman said the […]

AACR: Early Trovagene data offer hope for KRAS-mutant colon cancer
| FierceBiotech

Amgen may be leading the race to develop a KRAS inhibitor, but its candidate hasn’t logged the same success in colon cancer as it has in lung cancer. Early data out of the annual meeting of the American Association for Cancer Research (AACR) suggest a different route to treating patients with KRAS-mutated colon cancer—including those […]